Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL7485384 | 0.93 | SMN1; SMN2 (0.45) | TDP1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6955711 | 0.80 | TDP1 (0.50) | TDP1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6006476 | 0.80 | SMN1; SMN2 (0.44) | TDP1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6596781 | 0.80 | SMN1; SMN2 (0.44) | TDP1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6006563 | 0.80 | SMN1; SMN2 (0.44) | TDP1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1516437 | 0.78 | SMN1; SMN2 (0.54) | HTTSMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL1128585 | 0.78 | GAA (0.66) | TDP1HTTSMN1; SMN2HSD17B10POLB | |
| SCHEMBL3723869 | 0.77 | AGER (0.51) | TDP1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL16448135 | 0.77 | SMN1; SMN2 (0.49) | TDP1SMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL23529284 | 0.76 | CYP11B1 (0.49) | TDP1HTTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9560848-B2 | Method and compositions for biofouling deterrence | CLEMSON UNIVERSITY (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2642994-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | Ligand Pharmaceuticals Incorporated (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2488486-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012068406-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| EP-1322620-A1 | BENZIMIDAZOLE AND INDOLE DERIVATIVES AS CRF RECEPTOR MODULATORS | Neurogen Corporation (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030055037-A1 | Benzimidazole and indole derivatives as CRF receptor modulators | NEUROGEN CORPORATION | 2003-03-20 | — | — | US | disclosed |
| WO-2002028839-A1 | BENZIMIDAZOLE AND INDOLE DERIVATIVES AS CRF RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055037-A1 | Benzimidazole and indole derivatives as CRF receptor modulators | CRHR1, CRH, HTR4 | TDP1 3664/4885HTT 1115/4885SMN1; SMN2 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.